SCHEMBL4859078

SCHEMBL4859078

Clc1ccc(Cn2cc(Br)c3ccncc32)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DYRK1A Q13627 2/20 0.51
NFATC1 O95644 1/20 0.51
GSK3B P49841 1/20 0.51
KCNH2 Q12809 2/20 0.50
KDM4C Q9H3R0 1/20 0.47
CYP19A1 P11511 4/20 0.45
CDK2 P24941 1/20 0.43
DYRK1B Q9Y463 1/20 0.43
CYP11B1 P15538 4/20 0.41
CYP11B2 P19099 4/20 0.41
CYP2A6 P11509 1/20 0.41
CYP2B6 P20813 1/20 0.41
TUBB4A P04350 1/20 0.40
TUBB P07437 1/20 0.40
TUBA3C P0DPH7 1/20 0.40
TUBA1B P68363 1/20 0.40
TUBA4A P68366 1/20 0.40
TUBB4B P68371 1/20 0.40
TUBB3 Q13509 1/20 0.40
TUBB2A Q13885 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4849658 0.87 DYRK1A (0.67) DYRK1ANFATC1GSK3BKCNH2KDM4C
SCHEMBL29801631 0.87 DYRK1A (0.66) DYRK1ANFATC1GSK3BKCNH2KDM4C
SCHEMBL4857531 0.87 DYRK1A (0.66) DYRK1ANFATC1GSK3BKCNH2KDM4C
SCHEMBL4856398 0.83 CYP11B1 (0.53) DYRK1ANFATC1GSK3BKCNH2KDM4C
SCHEMBL4849408 0.82 DYRK1A (0.53) DYRK1ANFATC1GSK3BKCNH2KDM4C
SCHEMBL4847918 0.80 DYRK1A (0.52) DYRK1ANFATC1GSK3BKCNH2KDM4C
SCHEMBL4856748 0.79 DYRK1A (0.48) DYRK1ANFATC1GSK3BKCNH2KDM4C
SCHEMBL4857328 0.78 CYP1B1 (0.42) DYRK1ANFATC1GSK3BKCNH2KDM4C
SCHEMBL4857216 0.77 DYRK1A (0.45) DYRK1ANFATC1GSK3BKCNH2KDM4C
SCHEMBL4855717 0.76 DYRK1A (0.43) DYRK1ANFATC1GSK3BKCNH2KDM4C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7456169-B2 Heterocyclic kinase inhibitors ABBOTT LABORATORIES INC. (US) 2008-11-25 US disclosed
US-20070254867-A1 Heterocyclic Kinase Inhibitors ABBVIE INC. 2007-11-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070254867-A1 Heterocyclic Kinase Inhibitors MAP3K20, MAP3K19, MAP4K2 DYRK1A 1117/4885NFATC1 1618/4885GSK3B 465/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.